Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
26 May 2017
Change (% chg)

$-0.02 (-3.48%)
Prev Close
$0.54
Open
$0.57
Day's High
$0.57
Day's Low
$0.52
Volume
31,542
Avg. Vol
26,063
52-wk High
$2.47
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

Repros Therapeutics Q1 loss per share $0.22
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Repros Therapeutics Inc :Repros Therapeutics Inc. reports first quarter 2017 financial results.Q1 loss per share $0.22.  Full Article

Repros names Larry Dillaha M.D. its permanent president and CEO
Monday, 10 Apr 2017 09:18am EDT 

Repros Therapeutics Inc - : Repros names Larry Dillaha, M.D., its permanent president and ceo . Dillaha has also been named to board, filling an existing vacancy . Dillaha was previously chief executive officer of Cavtherx, an inception stage biotechnology company .Dillaha has been serving as president, chief executive officer on an interim basis since February 1, 2017.  Full Article

Repros Therapeutics meets with FDA to discuss Proellex in treatment of uterine fibroids
Monday, 10 Apr 2017 09:15am EDT 

Repros Therapeutics Inc : Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids . Before meeting, was notified meeting would be Type C/guidance meeting, rather than Type B/end of Phase 2 meeting as previously expected . Company intends to announce further information following receipt of additional guidance from FDA on oral Proellex . Company expects to submit additional information and a proposed clinical protocol within a month on oral Proellex . FDA confirmed Proellex to continue on current partial clinical hold . Proellex to continue on partial clinical hold while FDA consult's with its liver experts regarding previously disclosed effects on liver .FDA agreed to accept additional information from co, its panel of liver experts for consideration by FDA's internal advisory liver team.  Full Article

Repros Therapeutics Inc reports • Q4 loss per share $0.16
Friday, 31 Mar 2017 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results .Q4 loss per share $0.16.  Full Article

Repros announces new CEO
Thursday, 2 Feb 2017 09:15am EST 

Repros Therapeutics Inc : Repros announces new CEO . Says ceo and president Joseph S. Podolski resigned .Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately.  Full Article

FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism
Tuesday, 6 Dec 2016 08:01pm EST 

Repros Therapeutics Inc : Says intends to meet with FDA to discuss design of a definitive phase 3 study that incorporates advice of committee .FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism.  Full Article

Repros says groups showed improvement in Enclomiphene study
Monday, 15 Aug 2016 04:01pm EDT 

Repros Therapeutics Inc : Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men .All groups showed statistically significant improvement in all metabolic parameters tested..  Full Article

Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
Tuesday, 9 Aug 2016 04:25pm EDT 

Repros Therapeutics Inc :Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million.  Full Article

Repros Therapeutics Inc. reported Q2 EPS ($0.18)
Tuesday, 9 Aug 2016 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc. reports second quarter 2016 financial results .Q2 loss per share $0.18.  Full Article

Repros Therapeutics reports Q1 loss per share of $0.20
Tuesday, 10 May 2016 09:15am EDT 

Repros Therapeutics Inc : Repros therapeutics inc.® reports first quarter 2016 financial results .Q1 loss per share $0.20.  Full Article

More From Around the Web

BRIEF-Repros Therapeutics Q1 loss per share $0.22

* Repros Therapeutics Inc. reports first quarter 2017 financial results